** Shares of specialty pharma firm Scienture Holdings SCNX.O rise ~60% to $3.55 premarket
** SCNX says it is launching Rezenopy nasal spray 10mg, an opioid overdose emergency drug, through a collaboration with Kindeva Drug Delivery L.P.
** Kindeva will manufacture and supply Rezenopy, while SCNX will own the marketing application and be responsible for sales, marketing, and distribution in the U.S.
** Rezenopy is the most potent version of naloxone HCl available in the market, co says
** SCNX gained 81.7% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。